Mark Wildgust

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

Oncology

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.